A recently published paper on a kinase and its importance in triggering cellular responses caps more than 12 years of research. Research led by Irving Coy Allen in the Virginia-Maryland College of ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

A common over-the-counter medication could significantly reduce the risk of colorectal cancer coming back. In a Swedish study, a low dose of aspirin was shown to slash recurrence in half for patients ...

Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. The complexity of its pathogenesis, involving genetic mutations, dysregulated signaling pathways, and compromised immune ...

A common over-the-counter medication could significantly reduce the risk of colorectal cancer coming back. In a Swedish study, a low dose of aspirin was shown to slash recurrence in half for patients ...

An international team of researchers co-led by Fred Hutchinson Cancer Center’s genetic epidemiologist Ulrike (Riki) Peters, PhD, has pinpointed what’s likely driving many colorectal cancers in people ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

Researchers from Japan report that they have characterized gene mutations in colorectal cancer (CRC) tumors with high tumor mutation burden that lack mutations in the major oncogenes. Their findings ...

Imagine popping an over-the-counter pill to remedy a headache. Or taking the same to treat inflammation or arthritis. And all the while, the same common pill is working to cut the risk of colon cancer ...